The impact of levothyroxine on thyroid autoimmunity and hypothalamic–pituitary–thyroid axis activity in men with autoimmune hypothyroidism and early-onset androgenetic alopecia by Krysiak, Robert et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0423-104X
e-ISSN: 2299-8306
The impact of levothyroxine on thyroid autoimmunity and
hypothalamic-pituitary-thyroid axis activity in men with
autoimmune hypothyroidism and early-onset androgenetic
alopecia
Authors:  Robert Krysiak, Karolina Kowalcze, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.a2021.0071




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Endokrynologia Polska" are listed in PubMed.
The final version may contain major or minor changes. 
Powered by TCPDF (www.tcpdf.org)
The  impact  of  levothyroxine  on  thyroid  autoimmunity  and  hypothalamic-pituitary-
thyroid  axis  activity  in  men  with  autoimmune  hypothyroidism  and  early-onset
androgenetic alopecia
Short title: Levothyroxine, thyroid, and androgenetic alopecia
10.5603/EP.a2021.0071
Robert Krysiak1, Karolina Kowalcze2, Bogdan Marek,3,4 and Bogusław Okopień1
1Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia,
Katowice, Poland
2Department  of  Paediatrics  in  Bytom,  School  of  Health  Sciences  in  Katowice,  Medical
University of Silesia, Katowice, Poland 
3Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical
University of Silesia, Zabrze, Poland 
4Endocrinological Ward, Third Provincial Hospital, Rybnik, Poland
Correspondence  to: Robert  Krysiak,  Department  of  Internal  Medicine  and  Clinical
Pharmacology,  Medical  University  of  Silesia,  Medyków  18,  40–752  Katowice,  Poland.
Tel./fax 0048 322523902, e-mail: r.krysiak@interia.pl
Abstract
Introduction: Administration of testosterone or dehydroepiandrosterone to subjects with low
levels of these hormones was found to reduce thyroid antibody titres. Male-pattern baldness is
accompanied  by  mildly  increased  androgen  levels. The  present  study  was  aimed  at
investigating whether early-onset androgenetic alopecia determines the impact of exogenous
levothyroxine  on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis  activity in
young men with autoimmune hypothyroidism.
Material and methods: The study included 2 thyroid-antibody-matched groups of men with
autoimmune hypothyroidism: subjects with early-onset androgenetic alopecia (group 1; n =
24) and subjects with no evidence of hair loss (group 2; n = 24). All patients were treated with
exogenous  levothyroxine.  Circulating  titres  of  thyroid  peroxidase  and  thyroglobulin
antibodies, as well as levels of thyrotropin, free thyroxine, free triiodothyronine, prolactin,
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total testosterone, calculated bioavailable testosterone, dehydroepiandrosterone-sulphate, and
oestradiol were measured before levothyroxine treatment and 6 months later.  
Results:  In  both  study  groups,  levothyroxine  decreased  thyroid  antibody  titres,  reduced
thyrotropin levels and increased free thyroid hormone levels. However, these effects were less
pronounced in the men with early-onset  male-pattern baldness than in the control men. The
degree of reduction in antibody titres and thyrotropin levels correlated with baseline levels of
total  and calculated bioavailable testosterone,  as well  with baseline insulin sensitivity and
treatment-induced  improvement  in  insulin  sensitivity.  Concentrations  of  the  remaining
variables remained unchanged throughout the study period. 
Conclusions:  The  results  of  the  current  study suggest  that  the  benefits  of  levothyroxine
therapy in men with autoimmune hypothyroidism are less pronounced in individuals with
early-onset androgenetic alopecia.
Key  words:  androgenetic  alopecia;  hormones;  hypothalamic-pituitary-thyroid  axis;
levothyroxine; thyroid autoimmunity
Introduction
A more frequent prevalence of  autoimmune thyroid disease in women than in men may
result from differences in sex hormone secretion [1]. There are some arguments suggesting
that physiological concentrations of androgens minimize the risk of thyroid autoimmunity [2].
Subjects with Klinefelter's syndrome, the most common cause of male hypogonadism, are at
increased  risk  of autoimmune  hypothyroidism  [3].  Men  with  autoimmune  thyroid
disease were  characterized  by  lower  values  of  the  oestradiol:testosterone  ratio  than  men
without thyroid antibodies  [4].  Shorter AR (CAG)n repeats  of the androgen receptor gene,
associated with its increased transcriptional activity, correlated with a younger age of onset of
Hashimoto’s  thyroiditis  [5].  Finally,  exogenous androgens administered to  men with  their
deficiency  reduced  thyroid  autoimmunity  and  improved  activity  of  the  hypothalamic-
pituitary-thyroid axis in men. The decrease in thyroid antibody titres, which was paralleled by
the increase in thyroid's secretory capacity, was observed in testosterone-treated men with
autoimmune thyroiditis coexisting with hypotestosteronaemia [6], as well as in DHEA-treated
subjects  with  mild  autoimmune  thyroid  hypofunction  and  low  dehydroepiandrosterone-
sulphate (DHEA-S) levels  [7]. Testosterone replacement therapy also potentiated the impact
of vitamin D on thyroid autoimmunity and thyroid function  [8].  Because of relatively low
post-treatment androgen levels, these findings do not allow us to conclude whether elevated
concentrations of androgens affect thyroid autoimmunity and thyroid function.
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Androgenetic alopecia, commonly known as male-pattern baldness, is the most common
type of progressive hair loss disorder in men, affecting as much 30% of individuals by the age
of 30 years and 80% of men during their lifespan  [9, 10]. Hair loss typically involves the
temporal and vertex regions  and mid-frontal  scalp while sparing the occipital  region [10].
Androgenetic  alopecia diagnosed  before  the  age  of  30-35  years  often  occurs  in  first-
generation relatives of women with polycystic ovary syndrome and is commonly regarded as
the phenotypic equivalent  of polycystic  ovary syndrome in men,  which carries the risk of
developing obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease [11]. It
seems that early-onset androgenetic alopecia is a state of mild androgen excess. Compared
with subjects  with no evidence of hair loss, men with early-onset male-pattern baldness are
characterized  by  elevated  levels  of  testosterone  and  dehydroepiandrosterone-sulphate
(DHEA-S),  lower  levels  of  sex  hormone-binding  globulin,  and higher  values  of  the  free
androgen index [12]. The purpose of this study was to assess whether the presence of early-
onset androgenetic alopecia in men determines the impact of exogenous levothyroxine on
thyroid autoimmunity and hypothalamic-pituitary-thyroid activity.
Material and methods
The  study  protocol  was  approved  by  the  Institutional  Review Board  and  conducted  in
accordance with the Declaration of Helsinki. All included patients provided written informed
consent after receiving an explanation of the voluntary nature of their  participation and a
description of the study.
Patients
The  study  population  was  selected  from  young  men  (18–40  years  old)  with  untreated
autoimmune hypothyroidism. Individuals were considered eligible for enrolment if they had
the  following:  (a)  thyroid  peroxidase  antibody  (TPOAb)  titres  above  100 U/mL;  (b)
sonographic  features  of  Hashimoto’s  thyroiditis  (diffuse  hypoechoic  echogenicity,
parenchymal  heterogeneity,  hypoechoic  micronodularity,  echogenic  septations,  and
hypervascularity); (c) serum thyrotropin levels in the range between 4.5 and 10.0 mU/L; (d)
free thyroxine levels in the range between 10.1 and 21.2 pmol/L; and (d) free triiodothyronine
in the range between 2.3 and 6.5 pmol/L. The study population was divided into two groups,
each of which consisted of 24 patients. Power calculation showed that 21 subjects per group
were needed to detect a 20% difference in thyroid antibody titres between both groups, with
80% power and a significance level of 0.05. Three extra subjects per group were recruited in
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order  to  compensate  for  possible  withdrawals.  Group  1  included  men  with early-onset
androgenetic  alopecia,  defined  as  grade  3  vertex  or  more  alopecia  on  the  Hamilton  and
Norwood scale (used to classify the stages of male pattern baldness [13, 14]) by the age of 30
years. In turn, group 2, serving as a control group, included subjects with no evidence of hair
loss.  Both groups of patients were selected among a larger group of men with autoimmune
thyroid hypofunction (n = 162), using a computer program, with the aim of obtaining two
study populations, matched for age, body mass index, blood pressure, thyroid antibody titres,
and thyrotropin levels. In order to limit  the effect of seasonal fluctuations in the outcome
variables  approximately  half  of  the  participants  (n  =  25)  were  enrolled  in  August  or
September and the remaining 23 were enrolled in February or March.
The  exclusion  criteria  were  as  follows:  positive  serum antibodies  against  thyrotropin
receptor,  other  autoimmune  or  endocrine  disorders,  impaired  renal  or  hepatic  function,
malabsorption syndrome, body mass index above 35 kg/m2, any other serious disorder, any
pharmacotherapy, and poor compliance with the study protocol.
Study design
Over the entire study period, the participants were treated with exogenous levothyroxine. To
avoid erratic  absorption of  levothyroxine,  patients  were instructed  to  take this  drug on an
empty stomach 30–60 minutes before breakfast (between 7.30 and 8.30 a.m.). The drug was
administered at a starting daily dose of 37.5 μg. After two weeks, this dose was titrated to the
final daily dose (75 μg), which was administered for the following 6 months. Medication
adherence was assessed every two months by means of a four-item Morisky-Green test, and
the pill count and was regarded as satisfactory if all four questions in the Polish version of the
Morisky-Green  test were correctly  answered and the  percentage  of tablets returned ranged
between 0% and 10%.
Laboratory assays
All measurements were carried out in duplicate (to ensure the consistency of assessments) at
the beginning and at the end of the study.  Venous blood was drawn between 7.00 and 8.00
a.m. to avoid circadian variations in the assessed variables, after an overnight 12-h fasting
period. Plasma  glucose  and  creatinine  levels  were  measured  using  standard  enzymatic
methods (Roche Diagnostics, Basel, Switzerland). Serum titres of TPOAb and thyroglobulin
antibodies  (TgAb),  as  well  as  serum  levels  of  thyrotropin,  free  thyroxine,  free
triiodothyronine,  DHEA-S,  total  testosterone,  oestradiol,  sex-hormone  binding  globulin,
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prolactin,  and  insulin,  were  assayed  by  direct  chemiluminescence using  acridinium ester
technology  (ADVIA Centaur  XP Immunoassay  System,  Siemens  Healthcare  Diagnostics,
Munich, Germany). Bioavailable testosterone was estimated from total testosterone, and sex
hormone-binding  globulin  was  estimated  with  the  Vermeulen  formula,  using  the  online
calculator  (www.issam.ch/freetesto.htm).  The  homeostasis  model  assessment  1  of  insulin
resistance index (HOMA1-IR) was measured by multiplying fasting glucose [mg/dL] and
insulin [mU/L] divided by 405. The estimated glomerular filtration rate was calculated using
the Modification of Diet in Renal Disease study equation.
Statistical analysis
All  outcome  variables were  log-transformed  to  approximate  a  normal  distribution. Both
groups, including changes from baseline after adjustment for baseline values, were compared
by Student’s  t-tests  for  independent  samples.  Student’s  paired  t-test  was  used  to  identify
differences between the means of variables in each study group. The χ2 test was employed to
compare  the  proportional  data.   Correlations  were  assessed  using  Pearson's  correlation
coefficient  (r). The  level  of  significance  was  defined as  a  p-value corrected for  multiple
testing below 0.05. 
Results
At entry, there were no significant between-group differences in age, smoking habits, body
mass index, blood pressure, TPOAb and TgAb antibody titres, serum levels of thyrotropin,
free thyroid hormones, prolactin and oestradiol, as well as in the glomerular filtration rate
(Tab.  1  and 2).  Concentrations  of  DHEA-S total  testosterone  and calculated  bioavailable
testosterone, as well as values of HOMA1-IR, were higher in group 1 than in group 2.  No
significant adverse effects  or any other complications were reported over the entire study
period, and all participants completed the study protocol. 
 In  both  study groups,  levothyroxine  decreased  the  TPOAb and  TgAb titres,  reduced
thyrotropin levels and HOMA1-IR, and increased free thyroxine and free triiodothyronine
levels. All these effects were stronger in group B than in group A. Concentrations of prolactin,
DHEA-S, total testosterone, calculated bioavailable testosterone, and oestradiol, as well as the
glomerular  filtration  rate,  remained  unchanged  throughout  the  study period.  Both  groups
differed in post-treatment values of antibody titres, post-treatment levels of thyrotropin, free
thyroid hormones, DHEA-S total testosterone, bioavailable testosterone, and in HOMA1-IR
(Tab. 2). 
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At entry, antibody titres correlated with thyrotropin levels [TPOAb: r = 0.51 (p < 0.0001),
TgAb: r = 0.43 (p = 0.0005)], total testosterone [TPOAb: r = 0.31 (p = 0.0221), TgAb: r =
0.26 (p = 0.0355)], and calculated free testosterone [TPOAb: r = 0.35 (p = 0.0056), TgAb: r =
0.32 (p = 0.0041)]. TPOAb titres correlated also with DHEA-S [r = 0.28 (p = 0.0392)], while
androgen  levels  correlated  with  HOMA1-IR  [total  testosterone:  r  =  0.32  (p =  0.0195);
bioavailable testosterone: r = 0.41 (p = 0.0007); DHEA-S: r = 0.25 (p = 0.0458)]. Treatment-
induced  changes  in  antibody  titres  correlated  with  baseline  antibody  titres  [group  1  —
TPOAb: r = 0.34 (p = 0.0098), TgAb: r = 0.28 (p = 0.0402); group 2 — TPOAb: r = 0.37 (p =
0.0084), TgAb: r = 0.31 (p = 0.0187)], total testosterone [group 1 — TPOAb: r = -0.39 (p =
0.0012], TgAb: r = -0.35 (p = 0.0088); group 2 — TPOAb: r = 0.47 (p = 0.0002), TgAb: r =
0.25 (p = 0.0488)], and calculated bioavailable testosterone [group 1 — TPOAb: r = 0.43 (p =
0.0008), TgAb: r = –0.37 (p = 0.0069); group 2 — TPOAb: r = 0.44 (p = 0.0003), TgAb: r =
0.29 (p  =  0.0274)].  There  were  also  correlations  between  treatment-induced  reduction  in
antibody titres and the effect of treatment on thyrotropin levels [group 1 — TPOAb: r = 0.55
(p < 0.0001), TgAb: r = 0.48 (p = 0.0001); group 2 — TPOAb: r = 0.37 (p < 0.0075), TgAb: r
= 0.29 (p = 0.0283)] and on HOMA1-IR [group 1 — TPOAb: r = 0.40 (p = 0.0010), TgAb: r
= 0.28 (p = 0.0387); group 2 — TPOAb: r = 0.38 (p = 0.0040), TgAb: r = 0.24 (p = 0.0495)].
No other correlations were significant.
Discussion
Despite  the  selection  procedure  used  in  the  current  study,  the  subjects  with  early-onset
androgenetic alopecia had elevated levels of total and calculated testosterone and of DHEA-S,
which suggests that they are characterized by increased gonadal and adrenal steroidogenesis.
However,  the  androgen profile  of  these  individuals  differed  from those observed in  male
siblings of women with polycystic ovary syndrome, in whom elevated levels of DHEA-S
coexisted  with  decreased  values  of  calculated  bioavailable  testosterone,  which  suggested
impaired  conversion  of  dehydroepiandrosterone  to  androstenedione  or  androstenedione  to
testosterone [15]. This finding indicates that men with early-onset androgenetic alopecia are
phenotypically  distinct  from  brothers  of  women  with  polycystic  ovary  syndrome.  The
obtained  results  also  indicate  that  subjects  with  early-onset  male-pattern  baldness are
characterized  by impaired  insulin  sensitivity,  which  may partially  explain  their  increased
susceptibility to the development of obesity, metabolic syndrome, and type 2 diabetes [11]. 
Another  interesting  observation  resulting  from our  study is  that  men with  early-onset
androgenetic  alopecia  may  be  characterized  by  a  more  severe  course  of  Hashimoto’s
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thyroiditis than men with normal hair growth. Although the selection procedure was aimed at
obtaining two study groups with similar titres of thyroid antibodies, TPOAb and TgAb titres
correlated with both total and bioavailable testosterone levels. Moreover, titres of TPOAb,
which are regarded as more sensitive and specific for thyroid autoimmune diseases than titres
of  TgAb [16],  correlated  with  DHEA-S  levels.  Enhanced  autoimmune  destruction  of  the
thyroid gland may be mediated by increased production of proinflammatory cytokines. In line
with  this  explanation,  anabolic  steroids  induced  production  of  tumour  necrosis- and
interleukin-1 [17]  and  their  increased  production  by  inflammatory  cells  correlated  with
severity of autoimmune thyroiditis [18].
However,  the  major  finding  of  the  present  study  is  that  men  with  autoimmune
hypothyroidism benefit to a lesser extent from levothyroxine treatment if they have coexisting
early-onset androgenetic alopecia. This observation seems to be clinically relevant because
early-onset  male-pattern baldness can be easily diagnosed based on anamnesis and clinical
examination.  The  obtained  results,  as  well  as  previous  observations  about  increased
cardiometabolic risk10, show that early-onset androgenetic alopecia cannot be regarded as only
a cosmetic defect but also a real danger to health. In light of previously described effects of
androgen therapy on thyroid autoimmunity and on the results of thyroid function tests [6–8],  it
seems  that  there  exists  an  inverted  U-shaped  relationship  between  the  impact  of
pharmacotherapy on thyroid autoimmunity and androgen levels.  Therefore,  both androgen
deficiency  and  androgen  excess  may  induce  or  deteriorate  the  course  of  Hashimoto’s
thyroiditis.
The study design does not provide a mechanistic explanation for the obtained results. The
most plausible explanation is a direct modulatory effect of endogenous androgens. In line
with this hypothesis, the impact on antibody titres correlated with circulating levels of all
measured  androgens.  The  finding  that  this  correlation  was  strongest  for  calculated
bioavailable testosterone probably results from the fact that bioavailable testosterone is the
biologically active fraction of testosterone that is not tightly bound to sex hormone-binding
globulin, and more accurately than total testosterone reflects the clinical androgen state of
men  [19,  20].  Moreover,  if  calculated  by  Vermeulen’s  formula,  bioavailable testosterone
levels highly correlate with free testosterone levels measured by equilibrium dialysis [20].
According to the second explanation, a weaker effect of levothyroxine treatment may be
secondary to the impaired insulin sensitivity observed in the participants of the present study.
In line with this hypothesis, the degree of reduction in thyroid antibody titres correlated with
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both  baseline  and  treatment-induced  changes  in  HOMA1-IR.  Moreover,  Liu  et  al.  [21]
reported that TPOAb titres correlated with HOMA1-IR and the concentration of C-reactive
protein in non-obese individuals with normal thyroid function, suggesting that mild deviation
of thyroid function within the normal range, chronic inflammation, and insulin resistance may
be  a  link  between  thyroid  autoimmunity  and  metabolic  abnormalities  in  the  non-obese
population. The presence of correlations between total and bioavailable testosterone levels
and HOMA1-IR may indicate that elevated androgen levels increase insulin resistance, which
is in line with previous findings of our research team [22]. If this explanation is correct, men
with  autoimmune  hypothyroidism  may  be  candidates  for  combined  administration  of
levothyroxine with metformin. Interestingly, metformin administered to subjects with primary
thyroid hypofunction reduces elevated thyrotropin levels [23], and by modulating thyrotrope
function it may potentiate the impact of levothyroxine on hypothalamic-pituitary-thyroid axis
activity.
The association between early-onset androgenetic alopecia and levothyroxine action on
thyroid  autoimmunity  and  hypothalamic-pituitary-thyroid  axis  activity  is  unlikely  to  be
mediated by oestrogens or prolactin. The conversion of testosterone to oestradiol catalysed by
aromatase may in subjects with early-onset androgenetic alopecia theoretically result in mild
oestrogen excess. However, this  explanation is not supported by the results of the current
study. There were no differences in oestradiol levels (which were within the reference range),
levothyroxine produced a neutral effect on oestradiol concentrations, while oestradiol levels
did not correlate with levothyroxine-induced changes in antibody titres or hormone levels.
The obtained results cannot be also attributed to prolactin excess, reported in  up to 22% of
patients with subclinical thyroid hypofunction [24] and more frequently observed in men with
adult-onset  androgenetic  alopecia  [12].  Although  this  hormone  exerts  a  complex
proinflammatory  effect  (impairing  the  negative  selection  of  autoreactive  B  lymphocytes
during  B  cell  maturation,  stimulating  the  maturation  of  T  cells,  inhibiting  apoptosis  of
lymphocytes, and enhancing the proliferative response to antigens and mitogens [25, 26]), its
levels in the current study remained unchanged and did not correlate with antibody titres and
hypothalamic-pituitary-thyroid axis activity. 
Our study has several limitations that should be considered when interpreting our findings.
Although it exceeded the required sample size, the study included a relatively small number
of participants, and the obtained results need to be confirmed in a large prospective trial. The
study design did not allow us to totally eliminate  the “regression toward the mean” effect,
arising  when  an  extreme  variable  on  the  first  measurement is  closer  to  the  average  on
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subsequent  measurements  [27].  Furthermore,  the  study  population  was  characterized  by
sufficient iodine [28] and low selenium [29, 30] intake. It is not certain whether the impact of
levothyroxine  treatment  is  similar  in  patients  inhabiting  iodine-deficient  and  selenium-
sufficient  areas.  Finally,  it  cannot  be  totally  excluded  that  the  effect  of  early-onset
androgenetic  alopecia  on  levothyroxine  action  is  different  in  euthyroid  subjects  with
autoimmune  thyroiditis  and  in  subjects  with  overt  autoimmune  hypothyroidism,  not
participating in the present study.  
Conclusions
Although levothyroxine treatment reduced thyroid antibody titres and altered thyrotropin
and thyroid hormone levels in both study groups, these effects were more pronounced in men
with normal hair growth than in men with early-onset androgenetic alopecia. The degree of
reduction  in  antibody titres  depended  on  baseline  androgen  levels,  as  well  as  on  insulin
sensitivity  and treatment-induced improvement  in  insulin  sensitivity. The obtained results
suggest  that  men  with  early-onset  androgenetic  alopecia  benefit  to  a  lesser  degree  from
levothyroxine therapy than the remaining men with autoimmune thyroid hypofunction.
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Table 1. Baseline characteristics of patients
Variable Group 1 a Group 2b p-value
[Group  1  vs. Group
11
2]
Number [n] 24 24 –
Age [years; mean (SD)] 31 (6) 30 (6) 0.5565
Smokers [%] 29 25 –
Body mass index [kg/m2; mean (SD)] 27.3 (5.5) 26.7 (4.8) 0.6891
Systolic  blood  pressure  [mmHg;  mean
(SD)]
121 (12) 119 (11) 0.5502
Diastolic  blood  pressure  [mmHg;  mean
(SD)]
85 (4) 84 (4) 0.3910
amen with early-onset androgenetic alopecia; bmen with normal hair growth; SD — standard
deviation
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Table 2. The effect of levothyroxine on thyroid antibody titres, hormones, insulin sensitivity,
and glomerular filtration rate in men with or without early-onset androgenetic alopecia and
autoimmune hypothyroidism
Variable Group 1 a Group 2b p-value
[Group  1  vs. Group
2]
TPOAb [IU/mL; mean (SD)]
At the beginning of the study
At the end of the study










TgAb [IU/mL; mean (SD)]
At the beginning of the study
At the end of the study










Thyrotropin [mIU/L; mean (SD)] 
At the beginning of the study
At the end of the study










Free thyroxine [pmol/L; mean (SD)] 
At the beginning of the study
At the end of the study










Free  triiodothyronine  [pmol/L;  mean
(SD)] 
At the beginning of the study
At the end of the study










Prolactin [ng/mL; mean (SD)
At the beginning of the study
At the end of the study 










DHEA-S [µmol/L; mean (SD)]
At the beginning of the study








p-value [post-treatment vs. baseline] 0.6809 0.7370 –
Total testosterone [nmol/L; mean (SD)]
At the beginning of the study
At the end of the study










Calculated  free  testosterone  [pmol/L;
mean (SD)]
At the beginning of the study
At the end of the study










Oestradiol [pmol/L; mean (SD)]
At the beginning of the study
At the end of the study










HOMA1-IR [mean (SD)] 
At the beginning of the study
At the end of the study










Estimated  glomerular  filtration  rate
[mL/min/1.73m2; mean (SD)] 
At the beginning of the study
At the end of the study











amen  with  early-onset  androgenetic  alopecia;  bmen  with  normal  hair  growth;
Statistically significant  results  are  marked  in  bold;  *the  impact  of  levothyroxine  [percent
changes from baseline after adjustment for baseline values] stronger than in group A
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